The Cancer That Always Comes Back - Until Now - Pancreatic Cancer Cured in Mice

Explore a groundbreaking Spanish study that achieved complete pancreatic tumor regression in mice by targeting the previously "undruggable" KRAS mutation through innovative combination therapy. Examine the molecular mechanisms behind pancreatic cancer's notorious resistance to treatment, focusing on how KRAS mutations drive tumor growth and survival. Analyze the research methodology that successfully overcame decades of therapeutic challenges by combining targeted inhibitors to prevent cancer cells from developing drug resistance. Understand the role of oncogenic KRAS in pancreatic cancer diagnosis, prognosis, and treatment, while reviewing the complex signaling pathways including ERK feedback mechanisms and MAPK signaling that maintain tumor progression. Learn about the specific combination therapy approach that not only achieved tumor regression but also prevented the development of resistance mechanisms that typically allow pancreatic cancer to return. Study the implications of this breakthrough research for future pancreatic cancer treatment strategies and examine related molecular targets including STAT3, SRC signaling, and other key pathways involved in cancer cell survival and proliferation.